chikungunya
viru
chikv
togavirida
alphaviru
etiolog
agent
chikungunya
fever
emerg
pathogen
recent
caus
sever
sever
outbreak
throughout
africa
southeast
asia
larg
outbreak
occur
la
island
oversea
depart
franc
mauritiu
sri
lanka
india
among
other
addit
autochthon
transmiss
seen
europ
outbreak
occur
itali
mainland
franc
suggest
temper
climat
support
viru
transmiss
furthermor
januari
european
centr
diseas
control
confirm
case
chikv
caribbean
island
st
martin
martiniqu
guadeloup
saint
barthelemi
mani
suspect
indic
spread
continent
america
possibl
chikv
transmit
human
aed
aegypti
aed
albopictu
mosquito
latter
import
vector
mani
recent
outbreak
due
mutat
envelop
gene
viru
allow
effici
transmiss
chikv
caus
denguelik
ill
associ
fever
rash
joint
pain
first
describ
modern
day
tanzania
term
chikungunya
deriv
makond
word
mean
bend
describ
postur
infect
individu
recent
us
armi
develop
liveattenu
vaccin
candid
call
chik
caus
transient
arthralgia
small
number
volunt
phase
ii
clinic
trial
experiment
subunit
recombin
virus
vlp
base
vaccin
also
describ
current
variou
stage
preclin
clinic
develop
howev
current
licens
vaccin
antivir
treatment
avail
chikv
altern
approach
develop
chikv
vaccin
use
viral
vector
complex
adenoviru
express
complet
chikv
structur
polyprotein
describ
shown
immunogen
protect
mice
howev
safeti
concern
regard
adenoviru
basedvector
may
limit
approach
contrast
modifi
vaccinia
viru
ankara
mva
test
human
proven
highli
safe
effect
protect
smallpox
mva
attenu
passag
vaccinia
viru
vacv
chicken
embryo
fibroblast
cef
result
larg
delet
genom
restrict
hostrang
passag
mva
lost
abil
product
infect
mammalian
cell
lead
abort
replic
vacv
far
reactogen
mva
use
previous
alphavirus
name
sindbi
venezuelan
equin
enceph
veev
virus
provid
robust
immun
latter
suggest
poxvirus
suitabl
vector
alphavirus
despit
presenc
high
level
neutral
antibodi
elicit
vacv
vector
veev
vaccin
candid
ineffect
provid
protect
airborn
infect
suggest
unabl
elicit
suffici
cell
mediat
immun
respons
shown
critic
protect
lethal
veev
enceph
mva
like
parent
viru
vacv
extens
test
vaccin
vector
express
viral
bacteri
parasit
antigen
shown
induc
humor
cellmedi
protect
immun
respons
furthermor
mva
deliv
effect
differ
rout
much
greater
stabil
live
viru
base
vaccin
approach
addit
mva
undergo
abort
replic
mammalian
cell
vector
stabil
problem
one
infect
cycl
occur
therefor
mva
vector
chikv
vaccin
would
attract
option
resourcelimit
countri
major
chikv
infect
occur
addit
volz
sutter
target
mva
ideal
vector
safe
next
gener
vaccin
chikv
mention
specif
attract
candid
pathogen
furthermor
garciaarriaza
et
al
success
use
mva
express
entir
chikv
structur
protein
vaccin
candid
indic
mva
provid
effect
immun
viru
report
describ
construct
immunolog
evalu
mvabas
chikv
candid
vaccin
base
protein
vaccin
test
two
mous
model
one
immunocompet
lack
interferon
signal
uniformli
protect
mice
defici
interferon
signal
use
mani
virus
shown
repeatedli
good
model
chikv
provid
mani
similar
human
infect
complet
protect
mortal
provid
mvachik
administ
primeboost
regimen
addit
provid
protect
mortal
highli
immunocompromis
mous
model
day
postvaccin
surprisingli
play
role
neutral
antibodi
appear
necessari
protect
chikv
contrari
recent
report
importantli
deplet
cell
vaccin
mice
result
loss
protect
succumb
infect
upon
challeng
wildtyp
chikv
indic
indispens
role
mvachik
immun
cell
protect
studi
carri
strict
accord
recommend
guid
care
use
laboratori
anim
nation
institut
health
iacuc
protocol
protocol
approv
institut
anim
care
use
committe
univers
wisconsin
african
green
monkey
kidney
cell
vero
atcc
babi
hamster
kidney
cell
atcc
cell
maintain
dulbecco
modifi
eagl
medium
dmem
gibco
carlsbad
ca
supplement
fetal
bovin
serum
fb
uml
penicillin
streptomycin
amphotericin
b
incub
chicken
embryo
fibroblast
cef
obtain
charl
river
charl
river
laboratori
intern
inc
wilmington
maintain
optimem
invitrogen
carlsbad
ca
supplement
fb
condit
chikungunya
viru
strain
la
reunion
chikvlr
genbank
use
construct
recombin
poxvirus
challeng
experi
viru
kindli
provid
dr
scott
weaver
univers
texa
medic
branch
galveston
texa
chikir
vaccin
candid
previous
describ
use
studi
posit
control
briefli
vaccin
construct
replac
subgenom
promot
cdna
chikv
clone
intern
ribosom
entri
site
encephalomyocard
viru
emcvir
shown
effect
safe
mice
nonhuman
primat
mva
viru
use
studi
obtain
bei
resourc
niaid
nih
ref
recombin
mva
viru
express
gfp
herein
call
mvagfp
base
wildtyp
mva
construct
previous
describ
product
recombin
mva
vaccin
chikv
gene
hereaft
call
pcr
amplifi
use
phusion
highfidel
dna
polymeras
new
england
biolab
ipswich
clone
special
modifi
poxviru
transfer
vector
chosen
previous
demonstr
neutral
antibodi
map
epitop
region
strongli
associ
protect
howev
includ
allow
proper
fold
protein
express
control
synthet
earlyl
vaccinia
viru
promot
use
vaccinia
viru
transcript
termin
previous
describ
vector
use
studi
contain
flank
sequenc
transfect
mvagfp
infect
cell
recombin
delet
iii
region
viral
genom
vector
contain
dsred
control
late
promot
allow
visual
base
select
permit
easi
distinct
recombin
red
wildtyp
green
virus
fig
recombin
mvachik
virus
gener
describ
previous
briefli
cef
seed
sixwel
plate
day
transfect
infect
multipl
infect
moi
pfucel
hour
mvagfp
cell
wash
pb
transfect
appropri
transfer
vector
use
fugen
hd
roch
diagnost
indianapoli
follow
manufactur
protocol
cell
monitor
presenc
red
fluoresc
hour
transfect
h
posttransfect
monolay
harvest
centrifug
min
cell
disrupt
time
follow
sonic
time
use
cup
sonic
disrupt
cell
extract
contain
recombin
virus
express
dsred
plate
onto
fresh
cef
cell
overlaid
agaros
h
recombin
virusgener
plaqu
detect
observ
fluoresc
pick
media
steril
filter
pipett
tip
cellviru
sampl
subject
freez
thaw
sonic
describ
plate
continu
passag
plaqu
passag
wildtyp
gfp
express
viru
observ
point
pcr
perform
confirm
presenc
recombin
viru
high
titer
viru
stock
prepar
pcr
posit
cultur
recombin
mvachik
virus
character
pcr
analysi
perform
final
viru
stock
ensur
genet
homogen
stabil
dna
extract
use
quickgdna
miniprep
kit
zymo
research
per
manufactur
instruct
zymo
research
irvin
ca
pcr
perform
use
phusion
polymeras
delet
iii
specif
primer
forward
revers
western
blot
analys
use
determin
vitro
express
pattern
mvachik
construct
purpos
cell
seed
cellswel
sixwel
plate
hour
hr
later
infect
moi
pfucel
optimem
absenc
fb
hr
infect
cell
harvest
lyse
use
radioimmunoprecipit
assay
buffer
ripa
mm
nacl
sodium
deoxychol
sd
mm
tri
ph
minut
min
gentl
agit
lysat
centrifug
min
rpm
supernat
collect
analysi
supernat
dilut
laemmli
buffer
biorad
richmond
ca
heat
min
load
biorad
precast
gel
gel
transfer
nitrocellulos
membran
use
transblot
turbo
blot
system
follow
manufactur
instruct
polyclon
serum
obtain
specificpathogenfre
spf
rabbit
inocul
vaccin
strain
chikv
use
probe
blot
dilut
develop
use
bcipnbt
alkalin
phosphatas
system
biorad
cell
use
immunocytochemistri
icc
experi
one
day
prior
infect
cell
plate
onto
glass
coverslip
place
insid
well
tissu
cultur
plate
follow
day
cell
infect
moi
pfucel
infect
allow
progress
hr
fix
use
paraformaldehyd
pfa
solut
phosphat
buffer
permeabil
cell
treat
triton
min
follow
mm
pb
min
room
temperatur
rt
block
pb
contain
bovin
serum
albumin
bsa
hr
rt
cell
incub
overnight
dilut
antichikv
polyclon
rabbit
serum
cell
subsequ
wash
three
time
pb
contain
tween
incub
dilut
antirabbit
igg
min
rt
cell
mount
use
vectashield
mount
medium
vector
laboratori
imag
acquir
use
evo
microscop
attach
camera
elisa
perform
describ
brewoo
et
al
briefli
elisa
plate
coat
purifi
chikv
carbon
buffer
ph
per
well
overnight
coat
plate
wash
twice
pb
wash
buffer
incub
block
buffer
bsa
pb
rt
hr
serum
sampl
serial
dilut
elisa
diluent
bsa
wash
buffer
ad
triplic
prepar
elisa
plate
plate
incub
rt
hr
known
neg
uninocul
posit
serum
sampl
mice
inocul
chikir
previou
studi
use
control
wash
per
well
dilut
horseradish
peroxidas
hrp
conjug
rabbit
antimous
igmg
abcam
inc
cambridg
ad
well
incub
rt
hr
plate
wash
per
well
tetramethylbenzidin
tmb
chromogen
sigma
st
loui
mo
ad
well
incub
dark
min
reaction
stop
ad
per
well
mm
colorimetri
measur
use
absorb
micropl
reader
biotek
winooski
vt
test
wavelength
nm
refer
wavelength
nm
highest
dilut
posit
exceed
mean
known
neg
serum
sampl
plu
three
standard
deviat
consid
endpoint
reciproc
valu
record
titer
group
four
sixweekold
femal
balbc
mice
harlan
spragu
dawley
indianapoli
six
tenweekold
mix
gender
interferon
signal
defici
mice
receiv
either
primari
primari
booster
immun
day
apart
vaccin
candid
via
intraderm
id
inject
hind
left
footpad
dose
unit
use
mva
vaccin
dose
chosen
either
lower
consist
mani
previou
report
mva
vector
vaccin
neg
control
group
immun
mvagfp
dose
posit
control
mice
vaccin
experiment
control
vaccin
viru
chikir
dose
unit
either
day
postprim
two
week
postboost
applic
anim
challeng
wildtyp
chikvlr
id
inocul
balbc
unit
hind
left
footpad
mice
bled
prior
boost
prior
challeng
follow
vaccin
monitor
level
neutral
antiviru
antibodi
passiv
transfer
studi
perform
use
mice
previous
describ
briefli
serum
collect
vaccin
balbc
mice
equal
volum
sampl
use
creat
pool
sera
mous
strain
separ
balbc
inoculum
inject
naiv
mice
intraperiton
ip
serum
chikir
vaccin
mice
use
posit
control
hour
passiv
transfer
mice
challeng
manner
describ
follow
challeng
mice
bled
three
day
consecut
monitor
viremia
via
maxillari
vein
except
balbc
experi
anim
experi
repeat
least
similar
result
deplet
studi
group
six
tenweekold
mice
n
vaccin
id
unit
mvachik
day
boost
day
day
post
prime
immun
mice
treat
ip
mab
mab
bio
x
cell
control
group
includ
untreat
immun
nonimmun
anim
treatment
group
challeng
id
unit
chikvlr
three
day
later
mice
treat
deplet
antibodi
day
postchalleng
deplet
effici
pbmc
day
infect
cell
subset
assess
flow
cytometri
stain
antimous
fitc
anti
mous
percp
mab
bd
bioscienc
data
shown
mice
monitor
morbid
mortal
two
week
histopatholog
perform
tissu
collect
mice
day
post
infect
dpi
footpad
leg
tissu
sever
euthan
mice
cut
half
expos
tissu
fix
buffer
pfa
two
day
hind
limb
decalcifi
pfa
contain
edta
week
chang
decalcif
solut
weekli
tissu
paraffin
embed
section
stain
hematoxylin
eosin
h
e
pictur
taken
use
soni
camera
attach
nikon
microscop
blood
sampl
collect
mice
follow
challeng
use
assess
viremia
viremia
assess
via
end
point
dilut
well
plate
seed
vero
cell
seed
night
cellswel
express
tissu
cultur
infecti
dose
per
ml
prime
studi
serum
sampl
taken
ten
day
postvaccin
measur
neutral
antibodi
studi
prime
boost
serum
sampl
collect
day
postprimari
vaccin
neutral
titer
determin
use
base
assay
modifi
grosfeld
et
al
briefli
sera
incub
min
inactiv
complement
serial
dilut
twofold
start
dilut
dilut
perform
dmem
describ
except
contain
fb
subsequ
unit
chikv
ad
well
dilut
media
virusserum
mixtur
incub
hr
follow
incub
mixtur
ad
well
plate
seed
vero
cell
monitor
day
presenc
cytopath
effect
cpe
cell
respons
analyz
previous
describ
briefli
mice
euthan
week
postboost
red
blood
cell
rbc
lysi
singlesplenocyt
suspens
resuspend
medium
supplement
fb
penicillinstreptomycin
mm
splenocyt
stimul
three
chikv
peptid
pool
cover
entir
protein
sequenc
respect
peptid
pool
use
concentr
separ
total
volum
h
presenc
brefeldin
peptid
pool
gener
gift
dr
daniel
streblow
synthes
thermo
fisher
scientif
cell
stain
intracellularli
apc
pe
pe
surfac
stain
fitc
antimous
percp
sampl
acquir
bd
facscalibur
analyz
flowjo
tree
star
graphpad
prism
softwar
la
jolla
ca
use
statist
analys
statist
analysi
viremia
level
perform
use
unpair
ttest
welch
correct
unequ
varianc
surviv
analysi
perform
assess
vaccin
effect
report
pvalu
mantelcox
test
genet
homogen
final
viru
construct
analyz
pcr
purifi
viral
dna
use
templat
amplif
primer
specif
flank
region
delet
iii
presenc
confirm
mvachik
band
expect
size
roughli
kb
fig
indic
mainten
insert
throughout
plaqu
select
mvagfp
bp
wildtyp
mva
bp
includ
control
addit
dna
sequenc
confirm
genet
alter
present
final
construct
data
shown
express
antigen
mvachik
recombin
virus
wildtyp
chikv
monitor
immunoblot
analysi
cell
pellet
lysat
supernat
infect
cef
test
protein
express
fig
kd
protein
detect
hr
pi
wildtyp
chikv
mvachik
infect
cell
mvagfp
mock
infect
cell
interestingli
cleav
protein
kd
detect
wildtyp
infect
cell
mvachik
lysat
suggest
lack
furin
cleavag
releas
peptid
precursor
protein
express
observ
supernat
chikv
infect
cell
detect
express
mvachik
suggest
protein
secret
determin
cellular
local
chikv
protein
mvachik
infect
cell
fix
probe
product
chikv
protein
use
polyclon
serum
order
determin
protein
reach
surfac
cell
singl
cell
set
permeabil
set
remain
intact
permeabil
cell
stain
much
brighter
fig
indic
chikv
protein
maintain
insid
cell
reach
cell
surfac
observ
wildtyp
chikv
infect
evalu
protect
efficaci
mvachik
vaccin
activ
immun
studi
conduct
mice
mous
strain
sensit
chikv
infect
experi
high
viremia
footpad
swell
succumb
infect
compar
immunocompet
strain
mice
mice
vaccin
describ
previous
challeng
wtchikv
mvachik
mvagfp
vaccin
mice
background
level
neutral
antibodi
wherea
chikir
vaccin
mice
seroconvert
fig
serum
collect
mice
postprim
postboost
test
total
antiviru
ig
gm
antibodi
elisa
clear
booster
effect
seen
mvachik
vaccin
mice
differ
postprim
postboost
sampl
highli
signific
p
fig
differ
profound
chikir
vaccin
mice
high
level
antiviru
antibodi
even
prior
boost
mvachik
chikir
group
protect
lethal
challeng
prime
boost
fig
addit
mvachik
mice
complet
protect
viremia
footpad
swell
fig
next
compar
histopatholog
footpad
mvachik
mvagfp
vaccin
mice
vaccin
mice
challeng
way
describ
subsequ
euthan
seven
dpi
assess
local
tissu
damag
follow
infect
footpad
mvachik
vaccin
mice
display
mild
inflamm
limit
muscl
damag
fig
contrast
footpad
mvagfp
mice
exhibit
sever
necrot
muscl
degener
edema
consist
previou
report
unvaccin
mice
fig
immunocompet
balbc
mous
model
select
evalu
immunogen
mvachik
use
previous
mva
chikv
follow
vaccin
low
level
neutral
antibodi
detect
mice
immun
mvachik
fig
immun
mice
challeng
wildtyp
chikv
determin
protect
viremia
viremia
detect
mvachik
vaccin
mice
n
fig
contrast
mvagfp
immun
mice
signific
level
viremia
p
determin
whether
antibodi
present
balbc
avg
neut
titer
undetect
neut
titer
vaccin
mice
suffici
protect
chikv
pool
immun
serum
passiv
transfer
mice
posit
control
addit
group
mice
treat
manner
pool
serum
avg
neut
titer
mice
vaccin
chikir
candid
vaccin
mice
treat
either
antimvachik
mvagfp
immun
serum
high
level
viremia
succumb
infect
fig
viremia
mice
passiv
transfer
serum
mvachik
vaccin
slightli
reduc
day
postinfect
howev
signific
p
contrast
chikir
immun
serum
provid
full
protect
viremia
mortal
fig
determin
role
cell
protect
first
investig
whether
mvachik
could
elicit
cell
respons
mice
measur
cytokin
product
upon
vitro
restimul
chikv
peptid
pool
cover
protein
sequenc
mvachik
immun
cell
produc
cytokin
upregul
costimulatori
molecul
significantli
higher
level
compar
mvagfp
vector
control
p
respect
fig
respons
observ
mvachik
splenocyt
stimul
peptid
pool
either
viral
protein
neg
control
fig
suggest
immun
respons
specif
addit
signific
differ
cytokin
monitor
includ
data
shown
furthermor
none
cytokin
test
show
differ
two
group
immun
cell
data
shown
similar
result
obtain
mvachik
immun
splenocyt
stimul
live
inactiv
whole
viru
prepar
data
shown
test
whether
mvachikspecif
immun
cell
inde
protect
deplet
cell
vaccin
mice
prior
challeng
wtchikv
mice
deplet
cell
control
nondeplet
mice
footpad
swell
surviv
challeng
fig
contrast
deplet
mice
along
mvagfp
control
succumb
infect
fig
mice
deplet
cell
also
high
level
viremia
footpad
swell
similar
mvagfp
control
fig
interestingli
cell
deplet
vaccin
mice
remain
healthi
without
footpad
swell
throughout
durat
studi
despit
develop
low
level
viremia
three
dpi
recent
reemerg
chikv
result
sever
explos
outbreak
underscor
need
effect
vaccin
sever
group
recent
employ
vari
strategi
construct
effect
vaccin
chikv
liveattenu
inactiv
adenoviru
vector
dna
vlp
base
strategi
test
shown
effect
provid
protect
chikv
despit
promis
result
vaccin
candid
drawback
safeti
stabil
product
broad
longliv
immun
respons
necessari
effect
vaccin
safeti
concern
remain
liveattenu
adenoviru
base
approach
inactiv
vlp
base
approach
requir
adjuv
normal
elicit
weak
cell
respons
contrast
mva
shown
safe
thousand
human
patient
also
everi
anim
test
furthermor
mice
defici
interferon
signal
experienc
clinic
symptom
follow
vaccin
mvachik
data
shown
previous
shown
mva
construct
safe
highli
immunodefici
scid
mice
addit
stabil
poxvirus
mva
abil
lyophil
optim
use
develop
countri
vaccin
need
coldchain
reliabl
maintain
mva
also
shown
stimul
broad
immun
respons
includ
induct
cellular
immun
describ
construct
express
preclin
efficaci
safeti
novel
mvachik
vaccin
candid
balbc
mice
immunocompet
protect
viremia
upon
challeng
mice
defici
interferon
signal
therefor
highli
suscept
chikv
infect
also
complet
protect
challeng
wtchikv
prime
boost
vaccin
addit
mice
protect
lethal
challeng
follow
prime
vaccin
mvachik
despit
robust
protect
observ
mice
produc
strong
neutral
antibodi
respons
follow
vaccin
although
vaccin
mice
develop
undetect
level
neutral
antibodi
produc
signific
amount
antiviru
antibodi
alphavirus
shown
protect
mice
passiv
transfer
mvachik
immun
serum
either
balbc
mice
protect
mortal
footpad
swell
follow
challeng
despit
slight
reduct
viremia
day
postinfect
mice
transfer
mvachik
immun
serum
p
suggest
antibodi
induc
vaccin
suffici
provid
protect
manner
could
due
fact
passiv
administ
immun
serum
significantli
dilut
circul
mice
evid
antibodi
suffici
protect
alon
provid
deplet
studi
conduct
mvachik
vaccin
mice
immun
tcell
deplet
despit
presenc
full
level
circul
antiviru
antibodi
mice
suscept
lethal
infect
antiviru
antibodi
essenti
protect
reduct
mortal
viremia
would
expect
deplet
mice
observ
data
suggest
mvachik
provid
protect
novel
mechan
base
sole
vaccin
induc
serum
circul
antibodi
antibodi
protect
via
passiv
transfer
deplet
remain
unclear
role
may
play
infect
mvachik
immun
mous
immunocytochemistri
western
blot
analysi
suggest
chikv
protein
maintain
insid
cell
furin
cleavag
occur
separ
respect
chosen
due
presenc
immunodomin
epitop
fact
previou
report
shown
could
effect
immunogen
alphavirus
addit
previous
observ
express
plasmid
presenc
requir
allow
place
outsid
plasma
membran
barth
et
al
also
demonstr
context
delet
semliki
forest
viru
transport
effici
plasma
membran
alon
therefor
absenc
surfac
infect
cell
complet
unexpect
may
proven
serendipit
allow
product
robust
immun
respons
could
provid
explan
lack
strong
humor
immun
respons
antibodi
would
limit
access
intracellular
protein
addit
improperli
fold
protein
would
expect
produc
mani
viru
bind
antibodi
neutral
data
suggest
recent
report
metz
et
al
suggest
produc
combin
baculoviru
system
immunogen
ie
produc
higher
neutral
antibodi
either
protein
alon
might
suggest
effici
togeth
obtain
robust
neutral
antibodi
respons
might
explain
mvachik
produc
neutral
antibodi
analysi
ex
vivo
cellular
respons
indic
mvachik
induc
antigenspecif
cell
cell
suggest
immun
cell
main
effector
cell
support
cellular
deplet
studi
show
protect
role
tcell
tcell
mediat
protect
previous
demonstr
anoth
alphaviru
veev
yun
et
al
abl
adopt
transfer
tcell
obtain
protect
multipl
immun
passiv
transfer
hyperimmun
serum
protect
interestingli
observ
differ
viral
titer
brain
surviv
mice
mvachik
vaccin
complet
protect
viremia
studi
recent
studi
base
anoth
vaccin
candid
chikir
shown
correl
protect
base
antibodi
establish
chikv
herein
present
data
suggest
specif
vaccin
use
may
one
way
provid
protect
chikv
mvachik
select
express
protein
could
argu
process
viru
substanti
differ
live
attenu
chikir
vaccin
wildtyp
chikv
result
infect
differ
set
epitop
gener
may
well
protect
via
altern
mechan
anoth
report
use
mice
defici
either
bcell
cell
data
present
suggest
antibodi
essenti
control
chikv
infect
cell
may
exacerb
diseas
hawman
et
al
found
similarli
mice
defici
b
tcell
less
sever
tissu
patholog
earli
chikv
infect
compar
wildtyp
control
howev
report
demonstr
viru
ineffici
clear
absenc
lymphocyt
suggest
possibl
dual
role
cell
earli
chikv
infect
tissu
damag
allow
order
control
viral
dissemin
observ
littl
evid
tissu
damag
vaccin
mice
possibl
mvachik
induc
specif
tcell
abl
effect
control
viral
replic
minim
collater
tissu
injuri
remain
possibl
tcell
requir
recal
respons
produc
antibodi
follow
challeng
although
unlik
mice
would
expect
earli
viremia
observ
vaccin
mice
fig
current
conduct
studi
determin
role
cell
protect
data
also
contrari
previou
report
teo
et
al
footpad
swell
observ
upon
antibodi
deplet
cell
chikv
infect
howev
studi
perform
mice
function
interferon
system
contrast
studi
use
vaccin
mice
without
proper
ifn
signal
thu
might
account
differ
observ
addit
recent
studi
human
show
strong
posit
tcell
respons
direct
protein
suggest
might
play
role
protect
immun
respons
viru
therefor
data
present
may
relev
human
infect
suggest
antibodi
may
mediat
protect
alphavirus
recent
publish
report
garciaarriaza
et
al
also
use
mva
vector
chikv
vaccin
candid
vaccin
express
entir
structur
protein
effect
induc
high
level
neutral
antibodi
respons
accompani
strong
tcell
specif
cell
mediat
respons
direct
contrast
result
report
report
protein
found
plasma
membran
cytoplasm
contrast
result
clearli
show
surfac
cell
figur
could
explain
immun
respons
drastic
differ
two
vaccin
candid
deplet
studi
indic
cell
indispens
protect
mvachik
report
mechan
protect
unclear
report
although
high
level
neutral
antibodi
induc
vaccin
like
protect
addit
vaccin
construct
garciaarriaza
et
al
use
entir
structur
protein
consist
contrast
vaccin
contain
portion
recent
report
shown
capsid
protein
contain
immunodomin
epitop
b
cell
therefor
exclud
vaccin
construct
favor
accessori
protein
furthermor
use
footpad
inject
close
mimic
intraderm
vaccin
human
might
expect
receiv
garciaarriaza
et
al
use
intraperiton
vaccin
given
human
therefor
could
potenti
induc
vastli
differ
immun
respons
deliv
anoth
rout
conclus
studi
demonstr
potenti
mva
effect
express
chikv
protein
gener
protect
immun
respons
despit
presenc
low
absent
neutral
antibodi
respons
mva
construct
express
chikv
protein
effect
sever
mous
model
provid
protect
two
critic
marker
diseas
viremia
joint
swell
vaccin
protect
despit
low
level
neutral
antibodi
normal
consid
golden
standard
protect
alphavirus
therefor
result
report
challeng
assumpt
antibodi
effect
provid
protect
chikv
alphavirus
futur
studi
combin
tcell
target
vaccin
like
one
present
along
tradit
vaccin
induc
strong
neutral
antibodi
could
provid
robust
comprehens
immun
respons
safe
easi
deliv
vaccin
regimen
howev
work
requir
character
protect
mechan
provid
